Abstract
In this issue of Blood, LaCasce et al present data on the incorporation of brentuximab vedotin (BV) with bendamustine (BVB) in patients with recurrent/refractory classical Hodgkin lymphoma (HL) that might be practice-changing.1
Original language | English (US) |
---|---|
Pages (from-to) | 1-3 |
Number of pages | 3 |
Journal | Blood |
Volume | 132 |
Issue number | 1 |
DOIs | |
State | Published - Jul 5 2018 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology